Liposomes As Carriers of Antimicrobial Agents or Immunomodulatory Agents in the Treatment of Infections

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1993 Jan 1

PMID 8477767

Citations 8

Authors

A F Lokerse

M T ten Kate

P M Melissen

W van Vianen

E W Van Etten

Affiliations

Soon will be listed here.

Abstract

Targeting of antimicrobial agents by means of liposomes is under investigation and may be of importance in the treatment of infections that prove refractory to conventional forms of antimicrobial treatment. The ability to achieve a significantly longer residence time of liposomes in plasma and limited uptake of liposomes by the mononuclear phagocyte system opens up new areas of investigation and potential therapeutic application. By manipulating the liposomal composition, rates of uptake and intracellular degradation can be influenced and thereby the rates at which liposome-encapsulated agents are released and become available to exert their therapeutic action. With respect to the targeting of macrophage modulators at the mononuclear phagocyte system by means of liposomes for maximal stimulation of the nonspecific antimicrobial resistance, experimental evidence is now available of the potential usefulness of liposomes as carriers of these agents. This approach may also be of importance for the potentiation of treatment of severe infections.

Citing Articles

Liposomal and Liposomes-Film Systems as Carriers for Bioactives from L. Petals: Physicochemical Characterization and Biological Potential.

cutovic N, Markovic T, Carevic T, Stojkovic D, Bugarski B, Jovanovic A Pharmaceutics. 2023; 15(12).

PMID: 38140083 PMC: 10747293. DOI: 10.3390/pharmaceutics15122742.

Calli Essential Oils Synergize with Lawsone against Multidrug Resistant Pathogens.

Soliman S, Alsaadi A, Youssef E, Khitrov G, Noreddin A, Husseiny M Molecules. 2017; 22(12).

PMID: 29261103 PMC: 6034512. DOI: 10.3390/molecules22122223.

Nanoparticles Suitable for BCAA Isolation Can Serve for Use in Magnetic Lipoplex-Based Delivery System for L, I, V, or R-rich Antimicrobial Peptides.

Vesely R, Jelinkova P, Hegerova D, Cernei N, Kopel P, Moulick A Materials (Basel). 2017; 9(4).

PMID: 28773383 PMC: 5502924. DOI: 10.3390/ma9040260.

Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Fernandez-Fernandez A, Manchanda R, McGoron A Appl Biochem Biotechnol. 2011; 165(7-8):1628-51.

PMID: 21947761 PMC: 3239222. DOI: 10.1007/s12010-011-9383-z.

Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration.

Bassissi F, Lespine A, Alvinerie M Parasitol Res. 2005; 98(3):244-9.

PMID: 16341879 DOI: 10.1007/s00436-005-0073-z.

References

Taylor R, Williams D, Craven P, Graybill J, Drutz D, Magee W . Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982; 125(5):610-1. DOI: 10.1164/arrd.1982.125.5.610. View

Bermudez L, Wu M, Young L . Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J Infect Dis. 1987; 156(3):510-3. DOI: 10.1093/infdis/156.3.510. View

COUNE A . Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience. Infection. 1988; 16(3):141-7. DOI: 10.1007/BF01644088. View

Melissen P, van Vianen W . Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or liposome-encapsulated muramyl tripeptide phosphatidylethanolamide. Infect Immun. 1992; 60(11):4891-7. PMC: 258245. DOI: 10.1128/iai.60.11.4891-4897.1992. View

Stevenson M, Baillie A, RICHARDS R . Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery. Antimicrob Agents Chemother. 1983; 24(5):742-9. PMC: 185936. DOI: 10.1128/AAC.24.5.742. View

Peeters P, Huiskamp C, Eling W, Crommelin D . Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology. 1989; 98 Pt 3:381-6. DOI: 10.1017/s003118200006145x. View

Emmen F, Storm G . Liposomes in treatment of infectious diseases. Pharm Weekbl Sci. 1987; 9(3):162-71. DOI: 10.1007/BF01967536. View

Parant M, CHEDID L . Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents. Infection. 1985; 13 Suppl 2:S251-5. DOI: 10.1007/BF01644439. View

Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E . Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991; 28 Suppl B:73-82. DOI: 10.1093/jac/28.suppl_b.73. View

10.

Lokerse A, Roerdink F . Effect of lipid composition on activity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes. Antimicrob Agents Chemother. 1988; 32(10):1560-4. PMC: 175919. DOI: 10.1128/AAC.32.10.1560. View

11.

Tremblay C, Barza M, Fiore C, Szoka F . Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1984; 26(2):170-3. PMC: 284113. DOI: 10.1128/AAC.26.2.170. View

12.

Swenson C, Popescu M, GINSBERG R . Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol. 1988; 15 Suppl 1:S1-31. DOI: 10.3109/10408418809104463. View

13.

Adler-Moore J, Chiang S, Satorius A, Guerra D, McAndrews B, McManus E . Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother. 1991; 28 Suppl B:63-71. DOI: 10.1093/jac/28.suppl_b.63. View

14.

Lopez-Berestein G, Hopfer R, Mehta R, Mehta K, Hersh E, Juliano R . Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984; 150(2):278-83. DOI: 10.1093/infdis/150.2.278. View

15.

Szoka Jr F, Chu C . Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes. Antimicrob Agents Chemother. 1988; 32(6):858-64. PMC: 172296. DOI: 10.1128/AAC.32.6.858. View

16.

Desiderio J, Campbell S . Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis. J Reticuloendothel Soc. 1983; 34(4):279-87. View

17.

Ostro M, Cullis P . Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm. 1989; 46(8):1576-87. View

18.

KENDE M, Alving C, Rill W, Swartz Jr G, Canonico P . Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother. 1985; 27(6):903-7. PMC: 180183. DOI: 10.1128/AAC.27.6.903. View

19.

Fountain M, Weiss S, Fountain A, Shen A, Lenk R . Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J Infect Dis. 1985; 152(3):529-35. DOI: 10.1093/infdis/152.3.529. View

20.

Otani T, Une T, Osada Y . Stimulation of non-specific resistance to infection by muroctasin. Arzneimittelforschung. 1988; 38(7A):969-76. View